DEBA PHARMA
ActiveSummary
DEBA PHARMA has been active since 1988 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €6.2m and a net result of €2.1m. Equity is growing by about 12% per year across the filed financial years. Its solvency ranks better than 95% of 91 sector peers (NACE 21, financial year 2025). The computed 12-month bankruptcy probability is below 0.1% (very low).
Directors
Board 5
Day-to-day management 1
Permanent representatives 1
Not every act has been read: a resignation may still be missing
Mandate history
- Board
- Day-to-day management
- began earlier
| Name | Functions and periods |
|---|---|
| Frederik DEJONGHE |
|
| INFICOM |
|
| Johan DEJONGHE |
|
| Kristof DEJONGHE |
|
| Vincent DEJONGHE |
|
Owners and capital
Owners
1 ownerChain of control
- INFICOM
- DEBA PHARMA
Highest known parent: INFICOM. The sources do not say who stands above it.
Owners 1
- INFICOMparent98.67%
Sources: the companies' annual accounts, the acts in the Belgian Official Gazette and the LEI register. Annual accounts state the shareholders that notified the company under article 7:225 of the Code of Companies and Associations and the parent companies that consolidate it. The register of ultimate beneficial owners (UBO) is not public: who ultimately stands behind a natural person or a foreign parent is not stated here. A company that does not include these statements in its annual accounts, or does not have to, is not listed.